Intravesical lignocaine in the diagnosis of bladder pain syndrome
- Rajesh TanejaAffiliated withPushpawati Singhania Research Institute Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Introduction and hypothesis
To differentiate between the pain originating from urinary bladder and that due to other pelvic organs, using intravesical instillations of 2% lignocaine solution.
Twenty-two women with pelvic pain received intravesical instillation of 20 ml of 2% lignocaine solution. The intensity of pain was recorded by using visual analogue scale (VAS) just before, at 2, 10 and 20 min after intravesical instillation. Women who experienced a drop in the VAS score by 50% were termed as responders. All these women underwent cystoscopy under anaesthesia.
Fifteen out of 22 (68.18%) women experienced a substantial reduction in the pain. Thirteen out of these 15 women had features suggestive of BPS/IC on cystoscopy. Out of the seven non-responders, two women were found to have endometriosis, four were diagnosed as pelvic inflammatory disease and one had diverticulitis.
Intravesical lignocaine appears to be useful in excluding patients with pelvic pain originating from organs other than the urinary bladder.
KeywordsBladder pain syndrome Intravesical lignocaine
- Intravesical lignocaine in the diagnosis of bladder pain syndrome
International Urogynecology Journal
Volume 21, Issue 3 , pp 321-324
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Bladder pain syndrome
- Intravesical lignocaine
- Industry Sectors
- Rajesh Taneja (1)
- Author Affiliations
- 1. Pushpawati Singhania Research Institute, Press Enclave Road, Sheikh Sarai, Phase II, New Delhi, 17, India